BridgeMD
New treatment option for Chronic Kidney Disease(CKD)
Official title Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients
ClinicalTrials.gov ID: NCT06897605
What this study is testing
What is Dapagliflozin (DAPA)?
Dapagliflozin (DAPA) is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for chronic kidney disease(ckd).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additional benefits, including reducing the risk of cardiovascular events and renal complications.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults aged ≥ 18 years with CKD stage III or IV.
- Patients with anemia of CKD and a hemoglobin level \< 11.5 g/dL
- Patients are receiving erythropoiesis-stimulating agent therapy.
You likely can't join if
- Anemia due to causes other than chronic kidney disease, such as pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic syndromes.
- Patients with severe ketosis, diabetic coma, severe infection, perioperative complications, or severe trauma.
- Patients with acute heart failure, acute myocardial infarction, or stroke occurring within 6 months before enrollment in the trial.
- Patients with current malignancies or a history of malignancy within the past 2 years.
- Diagnosed with pure red cell aplasia.
- Patients with severe gastrointestinal bleeding.
See the full eligibility criteria
- Adults aged ≥ 18 years with CKD stage III or IV.
- Patients with anemia of CKD and a hemoglobin level \< 11.5 g/dL
- Patients are receiving erythropoiesis-stimulating agent therapy.
- Anemia due to causes other than chronic kidney disease, such as pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic syndromes.
- Patients with severe ketosis, diabetic coma, severe infection, perioperative complications, or severe trauma.
- Patients with acute heart failure, acute myocardial infarction, or stroke occurring within 6 months before enrollment in the trial.
- Patients with current malignancies or a history of malignancy within the past 2 years.
- Diagnosed with pure red cell aplasia.
- Patients with severe gastrointestinal bleeding.
- Pregnant or lactating females.
The study team makes the final eligibility decision.
Where it's taking place
- Al Mansurah, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Al Mansurah, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.